icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
 Back grey_arrow_rt.gif
 
 
 
Cohort Studies at EASL 2015
 
 
  EASL: Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of HCV in Patients With Severe Liver Disease: Interim Results of a Multicenter Compassionate Use Program - (04/29/15)
 
EASL: Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV Genotypes 1 and 3 - (04/24/15)
 
EASL: Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Reduced Renal Function: Real-World Experience from HCV-TARGET - (05/05/15)
 
EASL: All Oral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Report from HCV-TARGET - (04/23/15)
 
EASL: SAFETY AND EFFICACY OF THE COMBINATION DACLATASVIR-SOFOSBUVIR IN HCV GENOTYPE 1-MONO-INFECTED PATIENTS FROM THE FRENCH OBSERVATIONAL COHORT ANRS CO22 HEPATHER - (04/27/15)
 
EASL: Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: data from the French cohort- ANRS CO22 HEPATHER - (05/11/15)
 
EASL: Safety and efficacy of Sofosbuvir-containing regimens in the French cohort- ANRS CO22 HEPATHER - (05/11/15)
 
EASL: DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 3 INFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM - (04/24/15)
 
EASL: DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM - (04/24/15)
 
EASL: Efficacy of the oral Sofosbuvir-based combination in HCV genotype 4-monoinfected patients from the French observational cohort ANRS CO22 HEPATHER - (04/28/15)
 
EASL: Safety and efficacy of all-oral DAA regimens in HIV-HCV coinfected cirrhotic patients from the prospective ANRS CO13 - HEPAVIH cohort - (04/28/15)
 
EASL: Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER - (04/31/15)
 
EASL: Final evaluation of HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the TRIO network: academic and community treatment of a real-world, heterogeneous population - (04/30/15)
 
EASL: Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of Genotype 3 HCV; data from the TRIO network - (04/30/15)
 
EASL: Comparison of sofosbuvir +/- simeprevir in heterogeneous, real-world populations of HCV patients over 70 years; data from the TRIO network - (04/30/15)
 
EASL - The International Liver Congress 2015 50th Annual Meeting of the European Association for the Study of the Liver Vienna, Austria April 22-26